Intravascular Lithotripsy Devices Market (2026-2032)

Intravascular Lithotripsy Devices Market: Broader Use in Calcified Coronary and Peripheral Disease Reshapes Calcium Modification

The Global Intravascular Lithotripsy Devices Market was valued at approximately USD 1.16 billion in 2025 and is projected to reach USD 3.40 billion by 2032, expanding at a CAGR of approximately 16.6% during 2026–2032. Around 424,500 coronary and peripheral IVL procedures were performed globally in 2025, supporting demand for approximately 473,000 IVL catheters. The market is moving beyond its early role as a specialized technology for heavily calcified lesions and is becoming a more established part of complex coronary and peripheral intervention. Growth is being supported by a larger recognized burden of vascular calcium, wider physician familiarity, improved catheter deliverability, broader lesion eligibility, stronger reimbursement in major markets and growing competition across the calcium-modification category.

The addressable opportunity remains much larger than current IVL use. Calcification is common in patients with advanced coronary artery disease and peripheral artery disease, particularly among older adults and patients with diabetes or chronic kidney disease. In coronary intervention, moderate-to-severe calcium can prevent adequate lesion expansion and compromise stent deployment, while peripheral calcification can make long or occlusive lesions more difficult to treat. Shockwave Medical reports that more than one million patients worldwide have been treated with its IVL technology, indicating that the category has moved well beyond initial clinical adoption. Even so, IVL is still used in only a portion of calcified interventions, leaving substantial room for deeper penetration as physicians become more comfortable using dedicated calcium-modification strategies earlier in the procedure. 

Calcified Coronary Disease Becomes the Main Revenue Base

Coronary IVL accounted for approximately USD 816.8 million, or 70.3% of global IVL device revenue in 2025, making it the largest application segment. The segment is projected to reach approximately USD 2.38 billion by 2032 as IVL becomes more routinely considered in complex PCI involving severe calcification.

The commercial strength of coronary IVL comes from the direct impact of calcium on PCI quality. Rigid or circumferential calcium can restrict balloon expansion, interfere with stent delivery and increase the likelihood of under-expanded stents. This makes lesion preparation a more important part of procedural planning, particularly in older patients and those with diabetes, renal disease or multivessel coronary disease. IVL has gained traction because it can modify superficial and deeper calcium while fitting into a balloon-based workflow that is familiar to interventional cardiologists.

The segment has also benefited from a change in clinical use. IVL is no longer viewed only as a rescue option after standard balloon treatment fails. In high-volume centers, it is increasingly considered earlier when imaging or angiography shows severe calcium that is likely to compromise stent expansion. That change in physician behavior is more important to long-term market growth than simple PCI volume expansion because it increases the proportion of calcified cases in which IVL is planned rather than used selectively.

Medical Device Network has highlighted the relatively straightforward workflow of IVL compared with some atherectomy techniques, which reduces the training barrier for wider adoption. At the same time, more competitors are entering the category, which should expand physician awareness and increase the number of hospitals evaluating IVL as part of their calcium-modification strategy. 

Peripheral IVL Moves Into More Complex Lesions

Peripheral IVL generated approximately USD 344.6 million in 2025, representing 29.7% of global market revenue, and is projected to exceed USD 1.0 billion by 2032. The segment remains smaller than coronary IVL but offers greater room for expansion because calcified peripheral disease spans multiple vascular territories and adoption is still relatively uneven.

Peripheral artery disease affects more than 200 million people globally, while disease prevalence increases sharply with age. Patients with diabetes, renal impairment and chronic limb-threatening ischemia frequently present with more extensive arterial calcification, creating a population in which vessel preparation becomes particularly important. 

The peripheral opportunity differs from coronary IVL because the challenge is not only calcium severity but also lesion length, vessel size, chronic total occlusion and device crossing. Earlier IVL systems were more suitable for lesions that could already be crossed with a balloon catheter. Newer devices are increasingly designed for tighter and more complex anatomy, widening the number of lesions that can be treated.

This shift is especially important in femoropopliteal and below-the-knee disease, where diffuse calcification can limit conventional angioplasty and complicate subsequent drug-coated balloon or stent treatment. Peripheral IVL is therefore evolving from a selective adjunct in relatively accessible lesions toward a broader vessel-preparation option for patients with more advanced PAD.

Femoropopliteal Disease Remains the Largest Peripheral Opportunity

By vessel location, coronary arteries remain the dominant IVL application, but the peripheral market is becoming more differentiated as manufacturers develop catheters for specific vascular beds. Within peripheral IVL, femoropopliteal applications generated approximately USD 170 million in 2025, making them the largest peripheral anatomical segment. The segment is projected to approach USD 480 million by 2032.

Femoropopliteal disease represents an attractive market because it combines high intervention volumes with difficult mechanical conditions. Long lesions, vessel movement and heavy calcification can reduce the effectiveness of standard angioplasty and increase the importance of adequate vessel preparation. IVL is therefore gaining relevance as physicians seek to improve vessel compliance before definitive treatment.

Iliac artery IVL represented approximately USD 90 million in 2025 and could reach around USD 240 million by 2032. Iliac lesions are often heavily calcified but involve larger vessels, making IVL an important option where conventional balloon expansion is limited by rigid calcium.

Below-the-knee IVL generated approximately USD 60 million in 2025 and remains a smaller but strategically important segment. The opportunity is linked to advanced PAD and chronic limb-threatening ischemia, where calcification is often severe and treatment options are more limited. As catheter profiles improve and manufacturers move into smaller vessels, below-the-knee IVL could become one of the faster-growing peripheral applications through 2032.

Catheters Remain the Main Source of Market Revenue

By product type, coronary IVL catheters generated approximately USD 800 million in 2025, while peripheral IVL catheters contributed around USD 330 million. Generators, consoles and related accessories represented a much smaller share of the total market.

The revenue structure is heavily weighted toward disposable catheters, which gives the category a strong recurring-consumable profile. A hospital may install or gain access to a generator once, but each new procedure requires additional catheter use. This means market growth becomes increasingly linked to procedure frequency within established accounts rather than only to new system placements.

That installed-base effect strengthens the position of suppliers that already have broad physician familiarity and hospital access. Shockwave's existing coronary and peripheral portfolio gives it an important advantage because trained operators can increase utilization without adopting a completely new procedural platform.

Over time, however, competition could change the product mix. New systems that reduce capital requirements or offer alternative generator configurations may improve access in smaller hospitals and international markets. The catheter market is therefore likely to remain dominant, but the economics of platform entry could become more competitive.

Hospitals Continue to Control Most IVL Spending

Hospitals accounted for approximately USD 674 million of IVL revenue in 2025, representing about 58% of the global market. Their leadership reflects the concentration of complex PCI, peripheral revascularization, intravascular imaging and high-risk cardiovascular treatment in larger facilities.

Cardiac catheterization laboratories represented approximately USD 348 million, supported by the growing specialization of coronary and peripheral intervention. These centers are particularly important for IVL because adoption is strongly influenced by operator experience and procedural volume.

Ambulatory surgical centers generated approximately USD 81 million, while specialty cardiovascular centers accounted for roughly USD 58 million. These settings remain smaller but are likely to become more relevant in peripheral intervention as outpatient treatment expands.

The end-user landscape could gradually become less hospital-heavy if reimbursement supports migration of selected peripheral procedures into outpatient settings. That shift would increase the importance of disposable cost, procedural efficiency and reimbursement predictability, particularly in markets where IVL remains materially more expensive than conventional balloon angioplasty.

Imaging Makes Calcium Severity More Visible During PCI

The increasing use of IVUS and OCT is strengthening the role of dedicated calcium modification in complex PCI. Angiography can identify obvious calcification, but intravascular imaging provides more detail on calcium arc, thickness and distribution, which can influence whether standard balloon preparation is likely to be sufficient.

This matters because some coronary lesions that appear manageable on angiography may prove substantially more calcified when assessed with imaging. Better recognition of calcium severity can move these patients toward more deliberate lesion preparation before stenting.

Imaging therefore supports IVL adoption indirectly by improving patient selection. It also helps physicians evaluate whether IVL, atherectomy, specialty balloons or a combination of techniques is more appropriate for a particular lesion. As imaging-guided PCI becomes more common in complex disease, IVL should benefit from more consistent identification of lesions that require advanced calcium modification.

IVL Expands the Calcium-Modification Market Without Eliminating Atherectomy

The growth of IVL should not be viewed as a simple replacement of rotational or orbital atherectomy. Severe calcified lesions vary widely in morphology, crossing difficulty, calcium depth and vessel size, which means different technologies remain appropriate for different cases.

Atherectomy remains important where superficial calcium, lesion crossing or plaque modification requires a more aggressive approach. IVL is particularly relevant where deep or circumferential calcium limits vessel expansion. In some complex procedures, the two technologies can be used together rather than competitively.

This makes the broader calcium-modification market more valuable as complex PCI increases. Hospitals are not necessarily choosing one technology and abandoning the others; they are expanding the number of procedures in which dedicated calcium treatment is used at all.

Medical Device Network similarly describes IVL as part of a growing competitive calcium-modification category rather than a single replacement technology. The important market change is the increasing willingness of physicians to treat calcium actively before definitive stenting or angioplasty.

Reimbursement Separates Clinical Interest From Commercial Adoption

IVL has strong clinical appeal, but adoption remains sensitive to reimbursement because the disposable catheter adds a meaningful cost to the procedure. This is particularly important outside large tertiary hospitals, where budgets are tighter and reimbursement may not fully cover premium device use.

The United States has benefited from dedicated reimbursement pathways for coronary and peripheral IVL, helping hospitals adopt the technology more rapidly. This partly explains why U.S. IVL revenue remains substantially higher than international sales.

FastWave Medical identifies reimbursement as one of the important factors affecting broader access to IVL and future market development.

Internationally, reimbursement remains more fragmented. Countries with large PCI and PAD procedure volumes may still show relatively low IVL penetration if hospitals must absorb much of the incremental device cost. This creates a significant gap between clinical need and actual commercial use.

As competition increases, pricing could become more flexible. Lower catheter costs may reduce revenue per procedure but improve access across smaller hospitals, outpatient centers and price-sensitive markets.

United States Leads IVL Adoption as Calcified PCI Moves Into Routine Practice

The United States remains the largest IVL market, supported by high complex-PCI activity, established reimbursement and rapid use of dedicated calcium-modification technologies. Johnson & Johnson reported USD 897 million in U.S. Shockwave sales in 2025, representing nearly 78% of its USD 1.146 billion worldwide Shockwave revenue.

The clinical need is substantial. The American College of Cardiology estimates that moderate-to-severe coronary calcification is present in roughly one-third of patients undergoing treatment for stable coronary disease or acute coronary syndromes, while SCAI notes that calcified PCI carries higher short- and long-term procedural risk. This supports continued IVL use in complex PCI, particularly where calcium threatens adequate stent expansion.

The U.S. is also becoming a development market for harder lesions. Johnson & Johnson began the FORWARD CAD IDE study in April 2025 to evaluate its Javelin coronary IVL catheter in difficult-to-cross calcified coronary lesions, showing that the next adoption phase is moving toward anatomies that remain challenging for conventional balloon-based IVL.

Germany Combines High PCI Intensity With Rising Imaging Use

Germany is one of the most important IVL markets in Western Europe because of its exceptionally high coronary intervention volume. The German Heart Report 2025 recorded 353,512 PCI procedures in 2023, alongside 688,955 left-heart catheter examinations. Germany also recorded approximately 4,413 PCI procedures per million population, one of the highest rates reported in the ESC Atlas.

The country is also increasing use of intracoronary imaging, an important signal for advanced calcium management. IVUS use during PCI increased from 13,118 procedures in 2020 to 23,064 in 2023, raising its share from 3.8% to 6.5%. Greater imaging use improves recognition of calcium burden and can increase the number of lesions referred for advanced plaque-modification strategies.

Germany therefore represents a particularly strong Western European IVL market because high PCI volumes coincide with increasing use of imaging and complex coronary intervention. Western Europe remains more fragmented outside Germany because reimbursement and hospital procurement vary substantially between countries, limiting uniform adoption despite strong clinical interest.

Western Europe Gains Clinical Depth but Adoption Remains Uneven

Western Europe has become an important evidence and product-development region for IVL. At EuroPCR 2025, Shockwave presented data from 23 company-sponsored or funded studies, including three late-breaking presentations, reflecting the depth of clinical activity around coronary and peripheral IVL in European practice.

The region also provides early access to new calcium-modification systems, increasing competition beyond Shockwave. However, market penetration differs materially between Germany, France, the UK, Italy and Spain because reimbursement and purchasing pathways are not standardized across Europe.

Germany is therefore likely to remain the regional anchor, while wider Western European growth will depend more on reimbursement access and hospital adoption than on a shortage of eligible calcified patients.

Japan Stands Out for High PCI Volume and Exceptional Imaging Penetration

Japan represents the strongest high-value IVL opportunity in Asia-Pacific because of its large PCI base and extensive use of intravascular imaging. The Japanese J-PCI registry recorded 241,849 PCI procedures in 2023, and the registry now captures more than 247,000 PCI cases annually across 1,189 facilities, covering more than 90% of PCI-performing hospitals.

Japan is particularly relevant to IVL because intravascular imaging is deeply embedded in PCI practice. Historical multicenter data showed IVUS use in 84.8% of PCI procedures, rising above 90% in elective PCI, while Japanese Circulation Society data have reported IVUS use in approximately 80% of PCI cases and overall intravascular imaging guidance exceeding 90% when OCT was included.

This creates a favorable environment for IVL because calcium severity is more likely to be identified before stent deployment. Japan has also become an early launch market for next-generation technology: Johnson & Johnson made the Shockwave C2 Aero Coronary IVL Catheter available in both the United States and Japan in May 2026.

Japan's IVL opportunity is therefore driven less by rapid growth in total PCI volume and more by its high level of imaging-guided lesion assessment, established interventional expertise and early access to advanced coronary technologies.

Competition Broadens Beyond Shockwave as the Category Matures

Shockwave Medical remains the clear commercial leader after establishing IVL as a recognized cardiovascular device category. Its position is supported by a broad coronary and peripheral portfolio, more than one million patients treated globally and a large body of published clinical evidence.

The competitive environment is changing quickly. Johnson & Johnson's approximately USD 13.1 billion acquisition of Shockwave Medical confirmed the strategic value of the category, while Boston Scientific strengthened its IVL position through Bolt Medical. Abbott is also developing an IVL platform, and Elixir Medical has introduced a different calcium-modification approach through its LithiX technology.

The next stage of competition is likely to focus on catheter deliverability, lesion crossing, procedural simplicity, clinical evidence, generator requirements and price. Shockwave retains the strongest installed position, but competitors with large cardiovascular sales networks can narrow that advantage more quickly than small standalone entrants.

This will gradually change the market from a single-platform category into a broader competitive segment in which hospitals compare performance, workflow and economics rather than simply deciding whether to adopt IVL at all.

New Product Development Expands Treatable Anatomy

Product development is increasingly focused on lesions that earlier IVL systems could not easily reach or treat.

In coronary intervention, improved catheter profiles and crossing performance are opening access to tighter and more tortuous anatomy. Johnson & Johnson's Shockwave C2 Aero Coronary IVL Catheter, launched in 2026, was designed around improved deliverability and lesion crossing in calcified coronary disease.

Peripheral development is following a similar path. Newer systems are targeting severely narrowed and difficult-to-cross lesions that previously limited IVL use, particularly in advanced PAD.

This is an important evolution for the market because future growth increasingly depends on expanding treatable anatomy rather than simply increasing use in straightforward lesions. The category is becoming broader as device design moves closer to the clinical limits that previously restricted IVL adoption.

The Market Is Moving Into a Broader Adoption Phase

The IVL market has moved beyond initial clinical validation. More than one million patients have been treated with Shockwave technology, competing systems are entering the category, and new catheter designs are extending treatment into more difficult coronary and peripheral lesions.

Coronary IVL will remain the largest application through 2032, supported by increasing use in complex PCI and greater recognition of severe calcium through intravascular imaging. Peripheral IVL will grow from a smaller base, with femoropopliteal and below-the-knee disease providing important expansion opportunities.

The Global Intravascular Lithotripsy Devices Market is projected to increase from USD 1.16 billion in 2025 to approximately USD 3.40 billion by 2032, while annual treated procedures could approach 1.3 million.

The market's next phase will be defined by wider use in eligible calcified lesions, better access to difficult anatomy, stronger international reimbursement and increasing competition. As these factors develop, IVL is likely to become a more established part of calcium-modification practice across both coronary and peripheral intervention rather than remaining concentrated in selected high-complexity cases.